Inato has made improvements in its platform to boost patient access and inclusion in clinical trials globally.
This international platform links community-based sites with pharmaceutical firms seeking to focus on trial access and diversity.
By optimising trial matching with pharma sponsors and lowering duplications in the trial enrolment process, the latest enhancements will aid community research sites in providing further trials in their communities.
The platform of the company aids sites in analysing upcoming trial prospects and pursuing those that best suit them and their patients.
The new Check Your Fit tool of the company permits sites to carry out a two-minute evaluation to check if they are a suitable match for a certain study, thereby optimising the trial matching process for sites, as well as pharma sponsors.
This approach helps sites to avoid wasted time to progress with a trial opportunity that may not be suitable for the organisation or patient community.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
By leveraging the Inato platform, research sites can also reuse data from one trial to another.
Sites can direct their energy and time to more crucial trial-specific features that will boost the chances of being selected by a pharma sponsor by utilising the new pre-fill feature of Inato.
The pre-fill feature aids in reusing data from a similar prior enrolment plan.
Inato CEO and co-founder Kourosh Davarpanah said: “Our continued growth over the last year proves that sponsors are willing to think about access in a more patient-centric way by bringing trials into communities.
“This is a critical shift for research sites across all levels of experience that have been eagerly awaiting new opportunities to engage in research and bring medical innovations to the people they serve.”